(Q35749595)

10 August 2017

1 reference

title

Pharmacotherapy of somatoform disorders (English)

1 reference

10 August 2017

0 references

Brian A Fallon

1

1 reference

10 August 2017

1 April 2004

1 reference

Journal of Psychosomatic Research

10 August 2017

1 reference

10 August 2017

56

1 reference

10 August 2017

4

1 reference

10 August 2017

455-460

1 reference

Hypochondriacal fears and beliefs in DSM-III melancholia. Changes with amitriptyline.

10 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3999%2803%2900631-7

Reduction in hypochondriasis with treatment of panic disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3999%2803%2900631-7

An open trial of fluvoxamine for hypochondriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3999%2803%2900631-7

An open study of paroxetine in hypochondriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3999%2803%2900631-7

An open-label clinical trial of nefazodone in hypochondriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3999%2803%2900631-7

Imipramine an effective treatment for illness phobia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3999%2803%2900631-7

Treatment of body-dysmorphic disorder with serotonin reuptake blockers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3999%2803%2900631-7

Efficacy and safety of fluvoxamine in body dysmorphic disorder.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3999%2803%2900631-7

Delusionality and response to open-label fluvoxamine in body dysmorphic disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3999%2803%2900631-7

Clomipramine vs desipramine crossover trial in body dysmorphic disorder: selective efficacy of a serotonin reuptake inhibitor in imagined ugliness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3999%2803%2900631-7

A randomized placebo-controlled trial of fluoxetine in body dysmorphic disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3999%2803%2900631-7

Somatic Symptom Index (SSI): A New and Abridged Somatization Construct

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3999%2803%2900631-7

Fluvoxamine for somatoform disorders: an open trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3999%2803%2900631-7

Antidepressant-induced analgesia in chronic non-malignant pain: a meta-analysis of 39 placebo-controlled studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3999%2803%2900631-7

Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3999%2803%2900631-7

Does addition of low-dose flupentixol enhance the analgetic effects of low-dose amitriptyline in somatoform pain disorder?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3999%2803%2900631-7

Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3999%2803%2900631-7

Double-blind, randomized trial of bupropion SR for the treatment of neuropathic pain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3999%2803%2900631-7

Use of anticonvulsants for treatment of neuropathic pain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3999%2803%2900631-7

One-year follow-up of medical outpatients with hypochondriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3999%2803%2900631-7

10.1016/S0022-3999(03)00631-7

7 January 2021

Identifiers

DOI

1 reference

10 August 2017

1 reference

PubMed ID

15094032